Comments on the guideline debate

Affiliations

Comment

Richard Amerling et al. Clin J Am Soc Nephrol. 2007 Mar.

. 2007 Mar;2(2):208.

doi: 10.2215/CJN.00200107.

¹ Division of Nephrology and Hypertension, Beth Israel Medical Center, New York, NY 10003, USA. ramerling@usa.net

No abstract available

Comment on

Patient care guidelines: problems and solutions.
Narins RG, Bennett WM. Narins RG, et al. Clin J Am Soc Nephrol. 2007 Jan;2(1):1-2. doi: 10.2215/CJN.03120906. Epub 2006 Dec 6. Clin J Am Soc Nephrol. 2007. PMID: 17699376 Review.
Influence of industry on renal guideline development.
Coyne DW. Coyne DW. Clin J Am Soc Nephrol. 2007 Jan;2(1):3-7; discussion 13-4. doi: 10.2215/CJN.02170606. Epub 2006 Dec 6. Clin J Am Soc Nephrol. 2007. PMID: 17699377 Review. No abstract available.
Appraisal of evidence and control of bias in the kidney disease outcomes quality initiative guideline development process.
Van Wyck D, Eckardt KU, Uhlig K, Rocco M, Levin A. Van Wyck D, et al. Clin J Am Soc Nephrol. 2007 Jan;2(1):8-10. doi: 10.2215/CJN.02840806. Epub 2006 Dec 6. Clin J Am Soc Nephrol. 2007. PMID: 17699378 Review. No abstract available.